A5078291637- RNA Interference and Gene Delivery
- Advanced Drug Delivery Systems
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Nanoparticle-Based Drug Delivery
- Cancer Immunotherapy and Biomarkers
- Eosinophilic Disorders and Syndromes
- T-cell and B-cell Immunology
Centro Nacional de Biotecnología
2018-2023
Highlight Therapeutics (Spain)
2019
Poly I:C is a powerful immune adjuvant as result of its agonist activities on TLR-3, MDA5 and RIG-I. BO-112 nanoplexed formulation complexed with polyethylenimine that causes tumor cell apoptosis showing immunogenic death features which upon intratumoral release results in more prominent infiltration by T lymphocytes. Intratumoral treatment subcutaneous tumors derived from MC38, 4 T1 B16-F10 leads to remarkable local disease control dependent type-1 interferon gamma-interferon. Some degree...
Abstract MYC is an oncogenic transcription factor dysregulated in about half of total human tumors. Transcriptomic studies reveal more than 1000 genes regulated by but a much smaller fraction directly transactivated MYC. Virtually all Burkitt lymphoma (BL) carry chromosomal translocations involving oncogene. All endemic BL and sporadic are associated to Epstein-Barr virus (EBV) infection. The currently accepted mechanism that EBV the causing agent inducing translocation. Herein we show...
Abstract The molecular hallmark of Burkitt lymphoma (BL) is a chromosomal translocation that results in deregulated expression MYC oncogene. This present virtually all BL. an oncogenic transcription factor about half total human tumors, by or other mechanisms. Transcriptomic studies reveal more than 1000 genes regulated but much smaller fraction these directly activated MYC. All the endemic BL and many sporadic cells are associated to Epstein-Barr virus (EBV) infection. currently accepted...